Leaders in Healthcare Mergers & Acquisitions
36 Month Rule EXEMPT – Owned By Holding Company
Rare Opportunity!
Medicare Certified – Medicaid Pending
New – No Census
Never Billed so NO CAP ISSUES
ACHC Accreditation
Covers: Denver, Adams, Jefferson, Douglas, Arapahoe, Clear Creek, Delta, Douglas, Eagle, Jefferson, Lake, Mesa, Park, Pitkin, Summit, and Elbert Counties
Bring your own staff and start billing at closing (PTAN in 2 weeks)!
REDUCED Asking Price: to $397K Reference Number: 440557941629
Nevada Accredited Hospice for Sale
Rare Opportunity – 36 Month Rule Not Applicable!
Based in Henderson, Nevada
Covers all of Clark County
No Census Included
PTAN at Closing
ACHC Accredited
REDUCED Asking Price: $399K $297K
Reference Number: 35502592694
Nevada Accredited Hospice for Sale
Contact Vallexa Advisors: 586-623-5616
Cash equivalent to purchase price set aside to invest from currently available funds required
– Healthcare-specific industry experience required –
View other available healthcare opportunities by clicking HERE
Thinking of selling YOUR healthcare agency? Find out how by clicking HERE
Sell or Buy a Home Health Care Business: Your 2026 Guide
Primary keywords: sell a home health care business, sell my home health agency, buy a home care business, home care business for sale, home health care business for sale, home care agency for sale, home health care for sale, buying an established home health care business, home health agency for sale, hospice valuation.
The home health and hospice markets are evolving rapidly. Recent news shows Medicare increasing hospice payment rates by roughly 2.6% in FY 2026, raising the hospice cap and finalizing the transition to the HOPE quality reporting instrument (source). Meanwhile, private equity continues to invest in hospice—Linden Capital Partners recently acquired Agape Care Group—signalling confidence in long‑term growth. At the same time, hospices face workforce shortages, rising costs and new payment rules that squeeze margins (source). For home health and hospice owners thinking “How do I sell my home health agency?” or buyers searching “home care business for sale,” understanding valuations and market dynamics is essential.
When you decide to sell a home health care business, buyers will value it based on fair market value and future earnings potential. In recent valuations prepared by Vallexa Advisors:
These examples highlight the importance of accurate valuations. The Senior Living and Home Health sector generally trades at EBITDA multiples between 4.7× and 7.4×, depending on earnings size (source). Businesses represented by an M&A advisor achieve multiples 23% higher than sellers who go it alone (source).
Before going to market, owners should:
If you’re looking to buy a home care business or home health agency for sale, due diligence is crucial. Buyers should evaluate:
Many buyers are private equity firms or strategic consolidators who see opportunities to integrate home health and hospice services across the continuum. Financing remains available despite higher interest rates, but lenders are scrutinizing cash flows and regulatory risks more closely.
CMS’s FY 2026 hospice final rule increases payment rates by 2.6%, which the agency estimates will inject $750 million into the industry (source). Still, some operators argue the update lags inflation and rising labor costs. Coupled with the transition to the HOPE assessment instrument, hospices must invest in data collection and quality reporting.
In broader health care, CMS is piloting the GENEROUS model to lower Medicaid drug prices starting in 2026 (source). States participating in this model can purchase drugs at internationally indexed prices and share savings with CMS. More predictable Medicaid budgets could free up funds for home‑based services and influence valuations.
The workforce shortage is the root of many hospice problems. Agencies rely on clinicians, social workers, chaplains and volunteers to provide holistic care. Recruitment is difficult because the job requires clinical expertise, emotional intelligence and compassion. Staff are stretched thin and turnover increases when wages lag those of competing care settings (source). Retention strategies—flexible scheduling, mentorship programs, wellness initiatives and technology for documentation—are vital (source).
Home‑based care companies are expanding family caregiver education. Senior Helpers, for instance, operates training centers and support groups where family members learn to use equipment, perform transfers and reduce fall risks (source). These programs improve outcomes, keep patients out of hospitals and can even qualify caregivers for Medicaid wages in some states (source). For buyers, an agency’s caregiver support initiatives reflect quality of care and community engagement.
Vallexa Advisors specializes in health care M&A, including home health, hospice, palliative care and senior living transactions. We guide both sellers and buyers through:
You’ll also find our resources across our high‑authority sites: SellHomeHealth.com, HomeHealthSellers.com, HomeCare.ForSale, Hospice.ForSale and SellMyHomeHealth.com. These platforms connect sellers and buyers while protecting confidentiality.
The decision to sell a home health care business or buy a home care agency requires informed preparation. Valuations are shaped by financial performance, workforce strength, compliance, quality initiatives and market trends like payment rate updates and policy reforms. Whether you’re considering a sale now or in a few years, partnering with an experienced advisor like Vallexa Advisors ensures you capture maximum value while aligning with your strategic goals.
Ready to explore your options? Contact us today for a confidential valuation and personalized guidance. Visit VallexaAdvisors.com or call us to schedule your free consultation.
The process typically starts with an initial valuation, followed by preparing your financials, confirming license status, and organizing clinical and operational documentation. From there, Vallexa Advisors confidentially markets your agency as a home health care business for sale to vetted buyers, manages buyer inquiries, negotiates offers, and coordinates due diligence through closing.
A hospice valuation looks at adjusted EBITDA, payer mix, referral sources, compliance history, quality scores, staffing stability, and growth potential. Market trends, Medicare payment updates, and regional buyer demand also influence the multiple buyers are willing to pay for your hospice agency.
Every deal is different, but most transactions take 6–9 months from preparation to closing. The timeline includes valuation, packaging the opportunity, buyer outreach, management meetings, negotiation of the Letter of Intent, due diligence, and closing documentation.
Yes. Vallexa Advisors works with qualified buyers who want to buy a home care business, home health agency for sale, or hospice agency. We help buyers understand the financials, regulatory environment, and operational requirements so both sides move forward with clarity and realistic expectations.
Healthcare deals are highly regulated and require experience with Medicare, Medicaid, accreditation, surveys, clinical compliance, and payer contracts. Vallexa Advisors focuses exclusively on healthcare M&A, which means we understand licensing, valuations, and buyer expectations for home health, home care, hospice, and senior-care agencies. Our specialization helps you avoid costly mistakes and maximize value.
Strengthen your margins, clean up financials, stabilize census, diversify referrals, and reduce owner dependency by building a strong management team. Address any compliance or survey issues early. These steps can improve your valuation whether you plan to sell my home health agency or exit a hospice or home care business in the next 12–24 months.
Whether you want to sell a home health care business, explore a home health agency for sale, or understand your hospice valuation, you do not have to navigate the process alone. Vallexa Advisors connects qualified buyers and sellers, structures deals that protect both sides, and guides you from first conversation to final closing.
Take the first step toward a confident transaction with a specialized healthcare M&A team that understands your world.
Or visit VallexaAdvisors.com to learn more about our healthcare M&A services.
Turnkey and Fully Staffed, Owner will assist in Transition
Established in 2000
PTAN, NPI, Business License & Certificate of Need in Place
Average Daily Census : 65
ALOS : 75 days
No Cap Issues
Service Area: Covers all 4 Islands: St. Croix, St. Thomas, St. John and Water Island.
*Staff currently unaware of sale preparation, but high rate of employee retention is expected
Net income for YTD Sept. 2025 = $475,195
TOTAL Expected AEBITDA Run-Rate for 2025 = $633,000
Asking Price: $3,250,000
Reference Number: 33398123083
Contact Vallexa Advisors: 586-623-5616
Cash equivalent to purchase price set aside to invest from currently available funds required
– Healthcare-specific industry experience required –
View other available healthcare opportunities by clicking HERE
Thinking of selling YOUR healthcare agency? Find out how by clicking HERE
The agency serves all four U.S. Virgin Islands: St. Croix, St. Thomas, St. John, and Water Island.
It was established in 2000 and is well established with strong local relationships.
PTAN, NPI, business license, and Certificate of Need are in place.
Detailed financials available upon request and execution of a confidentiality agreement.
Yes—this is a turnkey, fully staffed operation. Staff are currently unaware of sale preparation; a high rate of employee retention is expected.
Yes, the owner will assist in the transition to support continuity of care and operations.
Please reference #33398123083 and submit buyer qualifications with an executed NDA to receive the confidential information memorandum and schedule a call.
The hospice landscape in late 2025 is anything but quiet. Federal fraud indictments, a brief government shutdown, and a new Medicaid pricing model are rippling across the sector. While these headlines can feel remote from day‑to‑day patient care, they directly influence how buyers evaluate hospice agencies. For owners thinking “what’s my hospice worth?” or considering a sale in 2026, understanding how these factors shape hospice valuation is critical.
According to Hospice News, two individuals in California were sentenced after defrauding the Medicare hospice benefit; one defendant received seven years and four months and was ordered to pay nearly $1.5 million in restitution. The article notes that California, Arizona, Nevada and Texas are now considered hotbed states for hospice fraud, with the state attorney general’s office warning that unscrupulous providers have entered these markets to exploit the Medicare program.
Fraud crackdowns are more than law‑enforcement news – they’re a valuation signal. Buyers are increasingly scrutinizing compliance programs, billing practices and leadership integrity. A hospice with clean billing, documented policies and a culture of compliance can defend a higher valuation multiple. Conversely, any hint of billing irregularities or weak internal controls will erode trust and reduce the purchase price.
The October 2025 federal shutdown briefly paused many government functions. Home health recertification surveys were mostly delayed, yet hospice surveys continued because the Consolidated Appropriations Act of 2021 earmarked mandatory funding for hospice oversight. Industry consultants note that complaint investigations also proceeded during the shutdown and that Accreditation Commission for Health Care (ACHC), Community Health Accreditation Partner (CHAP) and The Joint Commission (TJC) surveys were still authorized.
Why mention a three‑week shutdown in a valuation article? Because it underscores the importance of survey readiness. Buyers will look at your most recent recertification surveys and any corrective action plans. Agencies that maintain accreditation and proactively address survey findings signal operational resilience, which translates into stronger hospice valuations. Those who wait until they’re under the microscope risk lower offers.
CMS recently announced the GENEROUS model (Generous Medicaid Rebate Expansion for States) to lower drug prices starting in 2026. The program aims to align Medicaid drug costs with international prices and requires participating manufacturers to provide supplemental rebates. States will purchase drugs at lower prices and share the savings with CMS through reduced federal share of Medicaid spending. While the model focuses on drug pricing, it signals a broader trend: state Medicaid budgets could become more predictable, potentially freeing funds for hospice reimbursement and stabilizing payer mix.
For hospice owners, the takeaway is that policy changes affecting payer budgets indirectly influence valuations. When budgets tighten, buyers discount for reimbursement risk. When payment models stabilize or improve, valuations can lift. Staying abreast of these trends (and demonstrating how your payer mix will benefit) helps position your hospice for top offers.
News of fraud indictments, shutdown disruptions and Medicaid reforms can feel unsettling. Yet these same headlines create opportunities for well‑run hospices. Here’s how Vallexa Advisors positions owners to leverage market dynamics:
The hospice market remains attractive, but the rules are shifting. Fraud penalties, federal funding pauses and new payment models are raising the bar for compliance and strategic planning. To capture the highest value for your agency, you need a partner who understands both policy and valuation.
Get a confidential, data-driven hospice valuation that reflects the latest regulatory developments. Talk to a healthcare M&A specialist at Vallexa Advisors.
100% confidential · No upfront fees · Trusted by hospice owners nationwide
Note: This article is for informational purposes only and does not constitute legal or financial advice. Owners should consult professional advisors before making strategic decisions.
In November 2025, Hospice News reported fresh industry concerns about the 2026 Final Rule and the expanded rollout of the Hospice Outcomes & Patient Evaluation (HOPE) Tool. While much of the conversation has centered on compliance burden and workflow disruption, there’s another critical dimension hospice owners can’t ignore:
These changes are already influencing how buyers, lenders, and investors think about hospice valuation.
For owners considering a sale in 2026–2027, understanding how HOPE, quality reporting, and payment penalties flow into valuation is essential.
The HOPE Tool moves hospices from retrospective chart abstraction to real-time, multi-timepoint patient assessments. Instead of only collecting data at admission and discharge, hospices now report information at several standardized timepoints, all submitted electronically to CMS.
For details straight from CMS, see:
Historically, hospice valuation centered on metrics such as:
Those still matter, but HOPE and the 2026 Final Rule add a new layer of scrutiny. Buyers are increasingly treating HOPE-related performance as a proxy for:
In other words, HOPE doesn’t just measure care — it now influences how much a buyer is willing to pay.
Most buyers value hospices using some variation of:
Enterprise Value = Adjusted EBITDA × Valuation Multiple
Under HOPE, “adjusted EBITDA” may be further discounted if:
Agencies that cannot demonstrate reliable HOPE compliance may see downward adjustments to both EBITDA and the multiple during due diligence.
CMS has signaled that non-compliance with HOPE reporting thresholds can trigger payment penalties. Solutions vendors are already warning that incomplete or late submissions could result in up to a 4% reduction in Medicare payments, depending on HQRP performance.
From a buyer’s perspective, that means:
Owners who can show clean, timely HOPE submission logs and robust internal audit trails will be viewed as lower risk, higher value assets.
There is an upside. The same data that worries some hospices can become a
Hospices that consistently demonstrate:
will be able to prove their quality story with data. In a competitive sale process, that can justify higher valuation multiples and stronger deal terms.
If you’re thinking about exit timing, here’s how to position your hospice for a stronger valuation in a HOPE-driven world:
Use CMS’s own HOPE resources as a checklist and training foundation:
This turns abstract quality data into a valuation story buyers can underwrite.
Agencies that show a proactive compliance culture are far more likely to command premium pricing than those that “scramble to fix things” once buyers start asking questions.
HOPE and the 2026 Final Rule have added complexity to a market that was already nuanced. Partnering with an advisor who lives exclusively in healthcare M&A can make the difference between a defensive, price-driven sale and a competitive, premium process.
Vallexa Advisors works solely with healthcare businesses — including hospice, home health, home care, and senior care providers — to prepare, position, and sell agencies for maximum value.
Here’s how Vallexa Advisors can help hospice owners navigate this new landscape:
Explore more resources and listings on our sister platforms:
The rules governing hospice care — and the data that define “quality” — are changing quickly. Those changes are already impacting hospice valuation and deal terms.
If you’re thinking about selling in the next 12–24 months, now is the time to align your HOPE processes, compliance posture, and financial story.
Get a confidential, data-driven hospice valuation that reflects the HOPE Tool, the 2026 Final Rule, and today’s buyer expectations. Talk to a healthcare M&A specialist at Vallexa Advisors.
💼 Schedule Your Confidential Consultation
100% confidential · No upfront fees · Built for hospice owners
Hospice valuation is the process of estimating what your agency is worth to a buyer, usually based on adjusted EBITDA multiplied by a market multiple. Starting in 2026, the HOPE Tool (Hospice Outcomes & Patient Evaluation) feeds detailed quality and compliance data into that equation. Strong HOPE performance can support higher multiples, while poor scores or inconsistent reporting can increase perceived risk and lower valuation.
Not automatically. The 2026 Final Rule and HOPE Tool create more transparency around clinical quality, documentation, and compliance. Agencies that already document well, train staff on HOPE workflows, and maintain clean survey histories are more likely to protect or improve their hospice valuation. Agencies with gaps in data, late submissions, or compliance issues may see buyers discount the price to reflect added risk.
Buyers still focus on adjusted EBITDA, margins, and average daily census, but they now look closely at HOPE-related indicators as well. Key metrics include:
Focus on three areas: financials, quality data, and compliance. Normalize EBITDA (remove one-time and discretionary expenses), stabilize census, and review documentation for HOPE, surveys, and CAP exposure. Implement internal audits for HOPE, train staff on workflows, and track quality trends in a simple dashboard. When buyers can see clean numbers and strong quality data, they are more willing to pay top-of-market multiples.
Most hospice transactions still take about 6–9 months from launch to closing, but HOPE and 2026 Final Rule requirements can lengthen the preparation phase. Plan on 3–6 months of prep to clean up financials, documentation, and quality reporting before going to market. A well-prepared hospice will generally move faster through buyer due diligence and encounter fewer surprises.
With new HOPE reporting rules, HQRP penalties, and survey scrutiny, hospice deals are more technical than ever. A general business broker may not understand how HOPE data, CAP liability, or survey findings affect value and deal structure. A hospice-focused M&A advisor like Vallexa Advisors can interpret those details for buyers, position your agency correctly, and create a competitive process that typically leads to better pricing and cleaner terms.
You can request a confidential hospice valuation by contacting Vallexa Advisors directly. We review your financials, HOPE readiness, quality metrics, and market position to provide a realistic view of what your hospice could be worth in today’s 2026–2027 buyer environment.
Get started here:
Contact Us
Hospice valuation isn’t just a number—it’s the culmination of your organization’s hard work, quality of care and growth potential. If you’re considering a sale or want to understand what your business is worth, this guide will walk you through the valuation process, explain what drives value, and show you how to position your hospice for a premium multiple.
The hospice industry has seen meteoric growth, and valuations reflect both enthusiasm and caution. In the boom years of 2021–2022, some hospice transactions traded at multiples exceeding 30× EBITDA. Recently, valuations have moderated as buyers and sellers become more aligned. That said, quality assets with scale, clean compliance records and strong margins are still commanding healthy prices, often in the high single digits or low double digits.
View other available healthcare opportunities by clicking HERE
Contact Vallexa Advisors: 586-623-5616
Thinking of selling YOUR healthcare agency? Find out how by clicking HERE
Whether you’re preparing to sell your hospice agency or exploring what it’s worth in today’s market, Vallexa Advisors offers confidential, success-based guidance from experts who understand healthcare M&A. Get a free, no-obligation valuation and discover how to maximize your exit.
💼 Schedule Your Free Consultation100% confidential · No upfront fees · Trusted by healthcare sellers nationwide
Home Care Agency for Sale in the Central State of Pennsylvania
Est. In 2023
This is Non-Medical
State Licensed and Medicaid Certified
New buyer is eligible to apply for MCO’S
Serves Region 5, PA
Counties covered: Adams, Cambria, Dauphin, Fulton, Huntingdon, Juniata, Lancaster, Lebanon, Perry, and York.
CASH OFFER ONLY
Asking Price: $80K
Reference Number: 9385647852
This agency offers non‑medical home care services, including personal care, companion support and daily living assistance. It does not provide skilled nursing.
Yes. The agency is state licensed and Medicaid certified. A new buyer is eligible to apply for MCO (Managed Care Organization) contracts to expand its payer mix.
The agency serves Region 5 of Pennsylvania, covering the counties of Adams, Cambria, Dauphin, Fulton, Huntingdon, Juniata, Lancaster, Lebanon, Perry and York.
The home care agency was established in 2023 and has obtained its licensure and certification since then.
The asking price is $80,000. The seller is only considering cash offers. Reference Number: 9385647852.
Qualified buyers should have experience in home care or healthcare operations and must have the funds available to complete the purchase. Cash buyers only.
Contact Vallexa Advisors: 586-623-5616
Cash equivalent to purchase price set aside to invest from currently available funds required
– Healthcare-specific industry experience required –
View other available healthcare opportunities by clicking HERE
Thinking of selling YOUR healthcare agency? Find out how by clicking HERE
This non‑medical home care agency in Central Pennsylvania represents a valuable entry point or add‑on for home health providers. Licensed by the state and Medicaid certified, it provides personal care and companionship services across a multi‑county territory.
This opportunity is ideal for an established agency or entrepreneur seeking to expand into the Central Pennsylvania market with a fully licensed, Medicaid certified operation.
Owners of senior‑care facilities often ask the same questions: How do I sell my assisted living facility? What are hospice valuations? How do I sell my home health care business? Each sector—assisted living facilities, RCFEs (Residential Care Facilities for the Elderly), home health agencies, skilled nursing facilities and hospice businesses—has unique valuation drivers, regulatory issues and buyer pools.
In 2025 the market is both dynamic and confusing. Boutique senior‑care deals can fetch anything from 3× to 7× EBITDA depending on recurring revenue and operational quality (OffDeal). Publicly available data show that mid‑market senior‑care companies sell at multiples ranging from 6.5× to 9.9× EBITDA for assisted living and 4.3× to 7.9× for hospice care (First Page Sage). Larger platform transactions can command higher multiples, but only for the best assets; some large strategic buyers have temporarily stepped back because high asking prices exceed their return thresholds. Aveanna Healthcare, for example, recently said it is “not a buyer of hospices” because hospice valuations are trading between 12× and 20× EBITDA, while home health deals are in the 5× to 8× range (Hospice News).
Despite this volatility, Vallexa Advisors sees tremendous opportunity for well‑prepared sellers. As a specialist in healthcare mergers and acquisitions, Vallexa helps owners of assisted living facilities, RCFEs, hospice agencies, skilled nursing facilities, home health agencies and palliative‑care businesses navigate valuations, prepare for sale and maximize value. This guide compiles current data on valuation ranges, outlines the steps to sell different types of senior‑care businesses and explains why partnering with Vallexa increases your chances of a premium exit.
Valuation multiples. Data from First Page Sage’s 2025 senior‑care report shows that mid‑market assisted living businesses (EBITDA $500k–$1M) sold at ~6.5× EBITDA with revenue multiples around 2.3×. As EBITDA climbs toward $5M, multiples increase toward ~9.9× EBITDA (First Page Sage). Cap rates (NOI ÷ value) for assisted living facilities average around 7.6%, implying values roughly 13× NOI (First Page Sage).
Drivers of value. OffDeal’s 2025 valuation guide notes that recurring resident revenue yields the highest multiples (~5–7× EBITDA) while a mix of short‑term stays lowers multiples to ~4–5×; high turnover and frequent vacancies push multiples down to ~3–4× (OffDeal). Buyers prize recurring revenue stability, a diversified resident mix, strong operational procedures with reduced owner dependence, robust compliance and risk management, and clearly articulated growth opportunities.
In California’s RCFE market, the value depends heavily on whether real estate is included; you may be selling the business, the property or both.
EBITDA multiples. Hospice businesses generally trade at lower multiples than assisted living because of reimbursement risk and regulatory complexity. First Page Sage’s report places hospice multiples for $500k–$1M EBITDA at ~4.3× EBITDA, rising to ~7.9× EBITDA for larger operations (First Page Sage). Aveanna Healthcare’s CEO recently noted that hospice transactions can command 12×–20× multiples—so high that Aveanna is not currently buying hospices—while home health deals can be done at ~5×–8× (Hospice News).
Factors influencing value. Hospice valuations depend on both objective factors (cash flow, payer mix, EBITDA) and subjective ones (quality scores, clinical reputation, referral relationships). Operational maturity, compliance history and stable census can either elevate or compress multiples.
Typical multiples. While large home health platforms occasionally command higher valuations, most home health and non‑medical home care agencies trade at ~4×–7× EBITDA, similar to assisted living. Publicly available data show that buyers focus on clean financials, diversified referral sources, stable census, strong margins, payer diversification (Medicare/Medicaid/private pay), and clinical quality. Vallexa’s internal analysis notes that representation by experienced advisors often leads to higher proceeds—companies represented by an M&A advisor earned ~21% higher payouts than facilities that ran their own deal process (First Page Sage).
Skilled nursing facilities (SNFs) and other senior‑housing assets command distinct valuations. Cap rate data show that SNFs have higher cap rates (~12.4%), implying lower valuation multiples, due to heavier regulatory oversight and operational complexity. Active adult and memory‑care communities maintain cap rates around 6–9%, implying moderate multiples (First Page Sage). As with all senior housing, occupancy rates, payer mix, property age and local demographics heavily influence value.
High asking prices, interest‑rate uncertainty and regulatory risk have caused some large strategics to pause acquisitions. In October 2025, Aveanna Healthcare publicly stated it is “not a buyer of hospices” because valuations are too high—hospice multiples are 12×–20× compared with home health deals at 5×–8× (Hospice News). However, this doesn’t mean demand has vanished—it means that buyers are selective. Well‑prepared, high‑quality agencies still attract premium offers from private equity firms, family offices and regional strategics.
Whether you own an assisted living community, RCFE, hospice, home health or palliative‑care agency, Vallexa’s proven process ensures you extract maximum value:
Schedule a free, confidential valuation today and let Vallexa Advisors transform your hard‑earned business into a legacy sale.
Las Vegas NV Medicare Home Health Agency for Sale
Fully Staffed -Turnkey!
Past the CMS 36 Month Rule
CHAP Accredited
Medicare AND Medicaid Certified
25 Current Census
2025 Projected Revenue $700,000
2024 Revenue $549,716
2023 Revenue: $328,359
Counties Covered: Amador, Churchill, Clark, Esmerelda, and Nye
Asking Price: 799K
Reference Number: 2781905214
Contact Vallexa Advisors: 586-623-5616
Cash equivalent to purchase price set aside to invest from currently available funds required
– Healthcare-specific industry experience required –
View other available healthcare opportunities by clicking HERE
Thinking of selling YOUR healthcare agency? Find out how by clicking HERE
A Medicare certified home health agency in Las Vegas, Nevada. It is fully staffed and turnkey.
Yes. The agency is past the CMS 36 Month Rule, which supports a smoother ownership transfer.
The agency is CHAP accredited and Medicare certified.
There are 25 active patients at the time of this teaser.
2025 projected revenue is $700,000. 2024 revenue was $549,716 and 2023 revenue was $328,359.
Amador, Churchill, Clark, Esmerelda, and Nye.
$799,000. Reference Number: 2781905214.
Yes. Buyers must have cash equivalent to the purchase price available to invest and healthcare industry experience.
Customary transition support is available and can be discussed with qualified buyers.
Submit an inquiry with your name, company, proof of funds, and relevant experience to receive the NDA and next steps from Vallexa Advisors.
Amador, Churchill, Clark, Esmerelda, and Nye counties.
Reference Number: 2781905214
Qualified buyers may request more information by submitting an inquiry with proof of funds and brief background to Vallexa Advisors.